Loading...
Sotalol is a class III agent with potassium-channel and beta-blocker properties and a 2% to 8% risk of proarrhythmia, including torsades de pointes. Some advocate hospital admission to monitor QT interval prolongation and arrhythmias. This study reviewed outcomes for 120 patients hospitalized for initiation of sotalol for atrial arrhythmias; 104 were discharged on sotalol.
All patients had telemetry monitoring and a mean follow-up of 7.8 months; 80% had underlying heart disease and 95% had atrial fibrillation at the start of therapy. Over 20% of patients had significant arrhythmic complications (ventricular ectopic beats or tachycardia, bradycardia of less than 40 beats per minute, or QTc prolongation over 25% of baseline). Seven patients (5…